0001695357 false 0001695357 2022-05-17 2022-05-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 17, 2022

 

Provention Bio, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38552   81-5245912
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

55 Broad Street, 2nd Floor

Red Bank, NJ

 

07701

(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 336-0360

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

 

Name of each exchange on which

registered

Common stock, $0.0001 par value per share   PRVB   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Amendment to Inducement Plan

 

On May 17, 2022, the board of directors of Provention Bio, Inc. (the “Company”) approved an amendment to the Provention Bio, Inc. 2020 Inducement Plan (the “2020 Inducement Plan”) to increase the number of shares of the Company’s common stock available for issuance pursuant to equity awards granted under the 2020 Inducement Plan from 2,000,000 shares to 4,500,000 shares (the “Share Reserve”). In accordance with Nasdaq Listing Rule 5635(c)(4), the Company did not seek approval of the amendment to the 2020 Inducement Plan by its stockholders. Other than the increase in the Share Reserve, the terms and conditions of the 2020 Inducement Plan were not changed.

 

The foregoing is a brief description of the material terms of the 2020 Inducement Plan, as amended, and is qualified in its entirety by reference to the full text of the 2020 Inducement Plan, as amended, filed as Exhibit 10.1 to this Current Report on Form 8-K.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On May 17, 2022, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). As of the record date for the Annual Meeting, March 21, 2022, there were 63,399,304 shares of common stock outstanding and entitled to vote at the Annual Meeting. There were 46,812,374 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which represented 73.84% of the outstanding shares entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business. The following is a brief description of each proposal voted upon at the Annual Meeting and the final voting results for each proposal.

 

  1. Stockholders elected each of Ashleigh Palmer, Jeffrey Bluestone, Avery Catlin, Sean Doherty, Wayne Pisano, Nancy Wysenski and John Jenkins to serve until the next Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.
     
    The votes were cast for this matter as follows:

 

Nominees  Votes For   Votes Withheld   Broker Non-Votes 
Ashleigh Palmer   26,870,500    845,246    19,096,628 
Jeffrey Bluestone   15,597,680    12,118,066    19,096,628 
Avery Catlin   27,072,182    643,564    19,096,628 
Sean Doherty   24,445,979    3,269,767    19,096,628 
Wayne Pisano   21,187,622    6,528,124    19,096,628 
Nancy Wysenski   24,451,522    3,264,224    19,096,628 
John Jenkins   24,318,260    3,397,486    19,096,628 

 

  2. Stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, by the following vote:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes 
 26,392,587    1,137,164    185,995    19,096,628 

 

  3. Stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022, by the following vote:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes 
 45,510,507    1,126,436    175,431    0 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) The following exhibit is furnished with this report:

 

Exhibit No.   Description
     
10.1   Provention Bio, Inc. 2020 Inducement Plan, as amended.
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 20, 2022 Provention Bio, Inc.
     
    By: /s/ Thierry Chauche
      Thierry Chauche
      Chief Financial Officer